YMAB
- Y-mAbs Therapeutics, Inc.
()
Overview
Company Summary
Y-mAbs Therapeutics, Inc. (YMAB) is a biopharmaceutical company focused on the development and commercialization of innovative antibody-based therapies to treat cancer. The company specifically targets pediatric and adult patients with high-risk neuroblastoma, a rare and aggressive form of cancer that primarily affects the adrenal glands.
Y-mAbs is dedicated to improving the lives of patients and their families by developing novel monoclonal antibody therapies that specifically target and attack cancer cells. Their approach involves harnessing the power of the immune system to identify and eliminate cancer cells while minimizing harm to healthy cells.
The company's lead product candidate, naxitamab (also known as DANYELZA�), has received approvals from regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Naxitamab is an antibody that binds to the GD2 receptor, which is overexpressed in neuroblastoma cells. By targeting this receptor, naxitamab facilitates the immune system's ability to destroy cancer cells.
Y-mAbs is actively conducting clinical trials and development activities to expand the usage of naxitamab, both as a monotherapy and in combination with other therapies. The company is also exploring the potential of other pipeline products, including omburtamab and radiolabeled versions of antibodies, to address additional oncologic indications.
In summary, Y-mAbs Therapeutics, Inc. focuses on developing and commercializing antibody-based therapies, with the goal of providing effective treatment options for pediatric and adult patients with high-risk neuroblastoma and other cancers.